Plain-English translation of NCT06473961 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called GC101 TIL for people with advanced lung cancer that hasn't responded to standard chemotherapy and targeted drugs. GC101 TIL is made by taking immune cells from your own tumor, growing more of them in the laboratory, and then putting them back into your body to help fight the cancer.
Standard treatments like chemotherapy and targeted drugs stop working for many people with advanced lung cancer. This medication represents a different approach—using your body's own immune system to attack cancer cells—which may help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
First, you'll have surgery to remove a piece of your tumor so immune cells can be collected and grown in a laboratory—a process that takes several weeks. Once the cells are ready, you'll receive a brief hospital stay for conditioning treatment followed by an infusion of your own grown immune cells. The trial lasts about 3 years total, with regular clinic visits to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Juncell Therapeutics
Enrollment target
~20 participants
Started
October 2024
Primary completion
January 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shun Lu, M.D.
Shanghai Juncell Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.